CHD5 is required for neurogenesis and has a dual role in facilitating gene expression and polycomb gene repression

Developmental Cell

Volumn 26, Issue 3, 2013, Pages 223-236

  Egan, Chris M ^a   Nyman, Ulrika ^g   Skotte, Julie ^c   Streubel, Gundula ^a   Turner, Siobhán ^a   O'Connell, David J ^f   Rraklli, Vilma ^g   Dolan, Michael J ^a   Chadderton, Naomi ^a   Hansen, Klaus ^c   Farrar, GwynethJane ^a   Helin, Kristian ^c,d,e   Holmberg, Johan ^g   Bracken, Adrian P ^a,b  

^a TRINITY COLLEGE DUBLIN   (Ireland)

^b ADELAIDE AND MEATH HOSPITAL   (Ireland)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

^d UNIVERSITY OF COPENHAGEN   (Denmark)

^e University of Copenhagen   (Denmark)

^f UNIVERSITY COLLEGE DUBLIN   (Ireland)

^g KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CHD5 PROTEIN; NUCLEAR PROTEIN; POLYCOMB GROUP PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; EMBRYO; GENE; GENE ACTIVATION; GENE EXPRESSION; GENE LOCUS; GENE REPRESSION; GENE TARGETING; MOUSE; NEOCORTEX; NERVE CELL DIFFERENTIATION; NERVOUS SYSTEM DEVELOPMENT; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DOMAIN; UPREGULATION;

ANIMALS; CELL DIFFERENTIATION; CELL LINE, TUMOR; CEREBRAL CORTEX; DNA HELICASES; EMBRYONIC STEM CELLS; FEMALE; GENE EXPRESSION REGULATION, DEVELOPMENTAL; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HEK293 CELLS; HUMANS; MICE; MICE, INBRED STRAINS; NERVE TISSUE PROTEINS; NEUROBLASTOMA; NEUROGENESIS; NEURONS; POLYCOMB-GROUP PROTEINS; PREGNANCY; RETINA;

EID: 84881540507     PISSN: 15345807     EISSN: 18781551     Source Type: Journal    
DOI: 10.1016/j.devcel.2013.07.008     Document Type: Article

References (56)

1. Bagchi A., Papazoglu C., Wu Y., Capurso D., Brodt M., Francis D., Bredel M., Vogel H., Mills A.A. CHD5 is a tumor suppressor at human 1p36. Cell 2007, 128:459-475.
2. Bajpai R., Chen D.A., Rada-Iglesias A., Zhang J., Xiong Y., Helms J., Chang C.P., Zhao Y., Swigut T., Wysocka J. CHD7 cooperates with PBAF to control multipotent neural crest formation. Nature 2010, 463:958-962.
3. Bannister A.J., Kouzarides T. Regulation of chromatin by histone modifications. Cell Res. 2011, 21:381-395.
4. Berriz G.F., Beaver J.E., Cenik C., Tasan M., Roth F.P. Next generation software for functional trend analysis. Bioinformatics 2009, 25:3043-3044.
5. Bertrand N., Castro D.S., Guillemot F. Proneural genes and the specification of neural cell types. Nat. Rev. Neurosci. 2002, 3:517-530.
6. Bibel M., Richter J., Lacroix E., Barde Y.A. Generation of a defined and uniform population of CNS progenitors and neurons from mouse embryonic stem cells. Nat. Protoc. 2007, 2:1034-1043.
7. Boskovic G., Niles R.M. T-box binding protein type two (TBX2) is an immediate early gene target in retinoic-acid-treated B16 murine melanoma cells. Exp. Cell Res. 2004, 295:281-289.
8. Bracken A.P., Helin K. Polycomb group proteins: navigators of lineage pathways led astray in cancer. Nat. Rev. Cancer 2009, 9:773-784.
9. Bracken A.P., Dietrich N., Pasini D., Hansen K.H., Helin K. Genome-wide mapping of Polycomb target genes unravels their roles in cell fate transitions. Genes Dev. 2006, 20:1123-1136.
10. Breunig J.J., Silbereis J., Vaccarino F.M., Sestan N., Rakic P. Notch regulates cell fate and dendrite morphology of newborn neurons in the postnatal dentate gyrus. Proc. Natl. Acad. Sci. USA 2007, 104:20558-20563.
11. Brodeur G.M. Neuroblastoma: biological insights into a clinical enigma. Nat. Rev. Cancer 2003, 3:203-216.
12. Caron H., van Sluis P., van Hoeve M., de Kraker J., Bras J., Slater R., Mannens M., Voûte P.A., Westerveld A., Versteeg R. Allelic loss of chromosome 1p36 in neuroblastoma is of preferential maternal origin and correlates with N-myc amplification. Nat. Genet. 1993, 4:187-190.
13. Clapier C.R., Cairns B.R. The biology of chromatin remodeling complexes. Annu. Rev. Biochem. 2009, 78:273-304.
14. Ernst T., Chase A.J., Score J., Hidalgo-Curtis C.E., Bryant C., Jones A.V., Waghorn K., Zoi K., Ross F.M., Reiter A., et al. Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders. Nat. Genet. 2010, 42:722-726.
15. Flanagan J.F., Mi L.Z., Chruszcz M., Cymborowski M., Clines K.L., Kim Y., Minor W., Rastinejad F., Khorasanizadeh S. Double chromodomains cooperate to recognize the methylated histone H3 tail. Nature 2005, 438:1181-1185.
16. Fujita T., Igarashi J., Okawa E.R., Gotoh T., Manne J., Kolla V., Kim J., Zhao H., Pawel B.R., London W.B., et al. CHD5, a tumor suppressor gene deleted from 1p36.31 in neuroblastomas. J.Natl. Cancer Inst. 2008, 100:940-949.
17. Garcia I., Mayol G., Rodríguez E., Suñol M., Gershon T.R., Ríos J., Cheung N.K., Kieran M.W., George R.E., Perez-Atayde A.R., et al. Expression of the neuron-specific protein CHD5 is an independent marker of outcome in neuroblastoma. Mol. Cancer 2010, 9:277.
18. Gaspar-Maia A., Alajem A., Polesso F., Sridharan R., Mason M.J., Heidersbach A., Ramalho-Santos J., McManus M.T., Plath K., Meshorer E., Ramalho-Santos M. Chd1 regulates open chromatin and pluripotency of embryonic stem cells. Nature 2009, 460:863-868.
19. Harrelson Z., Papaioannou V.E. Segmental expression of the T-box transcription factor, Tbx2, during early somitogenesis. Dev. Dyn. 2006, 235:3080-3084.
20. Ho L., Crabtree G.R. Chromatin remodelling during development. Nature 2010, 463:474-484.
21. Holmberg J., Perlmann T. Maintaining differentiated cellular identity. Nat. Rev. Genet. 2012, 13:429-439.
22. Hu G., Wade P.A. NuRD and pluripotency: a complex balancing act. Cell Stem Cell 2012, 10:497-503.
23. Joshi S., Guleria R., Pan J., DiPette D., Singh U.S. Retinoic acid receptors and tissue-transglutaminase mediate short-term effect of retinoic acid on migration and invasion of neuroblastoma SH-SY5Y cells. Oncogene 2006, 25:240-247.
24. Kehle J., Beuchle D., Treuheit S., Christen B., Kennison J.A., Bienz M., Müller J. dMi-2, a hunchback-interacting protein that functions in polycomb repression. Science 1998, 282:1897-1900.
25. Kim J., Cantor A.B., Orkin S.H., Wang J. Use of invivo biotinylation to study protein-protein and protein-DNA interactions in mouse embryonic stem cells. Nat. Protoc. 2009, 4:506-517.
26. Kouzarides T. Chromatin modifications and their function. Cell 2007, 128:693-705.
27. Lim D.A., Huang Y.C., Swigut T., Mirick A.L., Garcia-Verdugo J.M., Wysocka J., Ernst P., Alvarez-Buylla A. Chromatin remodelling factor Mll1 is essential for neurogenesis from postnatal neural stem cells. Nature 2009, 458:529-533.
28. Margueron R., Reinberg D. The Polycomb complex PRC2 and its mark in life. Nature 2011, 469:343-349.
29. Matthay K.K., Villablanca J.G., Seeger R.C., Stram D.O., Harris R.E., Ramsay N.K., Swift P., Shimada H., Black C.T., Brodeur G.M., et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. N.Engl. J. Med. 1999, 341:1165-1173. Children's Cancer Group.
30. McDonel P., Costello I., Hendrich B. Keeping things quiet: roles of NuRD and Sin3 co-repressor complexes during mammalian development. Int. J. Biochem. Cell Biol. 2009, 41:108-116.
31. Mohn F., Weber M., Rebhan M., Roloff T.C., Richter J., Stadler M.B., Bibel M., Schübeler D. Lineage-specific polycomb targets and de novo DNA methylation define restriction and potential of neuronal progenitors. Mol. Cell 2008, 30:755-766.
32. Molyneaux B.J., Arlotta P., Menezes J.R., Macklis J.D. Neuronal subtype specification in the cerebral cortex. Nat. Rev. Neurosci. 2007, 8:427-437.
33. Morey L., Brenner C., Fazi F., Villa R., Gutierrez A., Buschbeck M., Nervi C., Minucci S., Fuks F., Di Croce L. MBD3, a component of the NuRD complex, facilitates chromatin alteration and deposition of epigenetic marks. Mol. Cell. Biol. 2008, 28:5912-5923.
34. Morin R.D., Johnson N.A., Severson T.M., Mungall A.J., An J., Goya R., Paul J.E., Boyle M., Woolcock B.W., Kuchenbauer F., et al. Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nat. Genet. 2010, 42:181-185.
35. Murawska M., Kunert N., van Vugt J., Längst G., Kremmer E., Logie C., Brehm A. dCHD3, a novel ATP-dependent chromatin remodeler associated with sites of active transcription. Mol. Cell. Biol. 2008, 28:2745-2757.
36. Musselman C.A., Mansfield R.E., Garske A.L., Davrazou F., Kwan A.H., Oliver S.S., O'Leary H., Denu J.M., Mackay J.P., Kutateladze T.G. Binding of the CHD4 PHD2 finger to histone H3 is modulated by covalent modifications. Biochem. J. 2009, 423:179-187.
37. Nikoloski G., Langemeijer S.M., Kuiper R.P., Knops R., Massop M., Tönnissen E.R., van der Heijden A., Scheele T.N., Vandenberghe P., de Witte T., et al. Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes. Nat. Genet. 2010, 42:665-667.
38. Okawa E.R., Gotoh T., Manne J., Igarashi J., Fujita T., Silverman K.A., Xhao H., Mosse Y.P., White P.S., Brodeur G.M. Expression and sequence analysis of candidates for the 1p36.31 tumor suppressor gene deleted in neuroblastomas. Oncogene 2008, 27:803-810.
39. Paul S., Kuo A., Schalch T., Vogel H., Joshua-Tor L., McCombie W.R., Gozani O., Hammell M., Mills A.A. Chd5 requires PHD-mediated histone 3 binding for tumor suppression. Cell Rep. 2013, 3:92-102.
40. Pavlidis P., Noble W.S. Matrix2png: a utility for visualizing matrix data. Bioinformatics 2003, 19:295-296.
41. Pietersen A.M., van Lohuizen M. Stem cell regulation by polycomb repressors: postponing commitment. Curr. Opin. Cell Biol. 2008, 20:201-207.
42. Potts R.C., Zhang P., Wurster A.L., Precht P., Mughal M.R., Wood W.H., Zhang Y., Becker K.G., Mattson M.P., Pazin M.J. CHD5, a brain-specific paralog of Mi2 chromatin remodeling enzymes, regulates expression of neuronal genes. PLoS ONE 2011, 6:e24515.
43. Reynolds N., Salmon-Divon M., Dvinge H., Hynes-Allen A., Balasooriya G., Leaford D., Behrens A., Bertone P., Hendrich B. NuRD-mediated deacetylation of H3K27 facilitates recruitment of Polycomb Repressive Complex 2 to direct gene repression. EMBO J. 2012, 31:593-605.
44. Reynolds N., O'Shaughnessy A., Hendrich B. Transcriptional repressors: multifaceted regulators of gene expression. Development 2013, 140:505-512.
45. Schnetz M.P., Bartels C.F., Shastri K., Balasubramanian D., Zentner G.E., Balaji R., Zhang X., Song L., Wang Z., Laframboise T., et al. Genomic distribution of CHD7 on chromatin tracks H3K4 methylation patterns. Genome Res. 2009, 19:590-601.
46. Schübeler D. Epigenomics: Methylation matters. Nature 2009, 462:296-297.
47. Schuettengruber B., Martinez A.M., Iovino N., Cavalli G. Trithorax group proteins: switching genes on and keeping them active. Nat. Rev. Mol. Cell Biol. 2011, 12:799-814.
48. Schwartzentruber J., Korshunov A., Liu X.Y., Jones D.T., Pfaff E., Jacob K., Sturm D., Fontebasso A.M., Quang D.A., Tönjes M., et al. Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature 2012, 482:226-231.
49. Simic R., Lindstrom D.L., Tran H.G., Roinick K.L., Costa P.J., Johnson A.D., Hartzog G.A., Arndt K.M. Chromatin remodeling protein Chd1 interacts with transcription elongation factors and localizes to transcribed genes. EMBO J. 2003, 22:1846-1856.
50. Sparmann A., Xie Y., Verhoeven E., Vermeulen M., Lancini C., Gargiulo G., Hulsman D., Mann M., Knoblich J.A., van Lohuizen M. The chromodomain helicase Chd4 is required for Polycomb-mediated inhibition of astroglial differentiation. EMBO J. 2013, 32:1598-1612.
51. Taverna S.D., Li H., Ruthenburg A.J., Allis C.D., Patel D.J. How chromatin-binding modules interpret histone modifications: lessons from professional pocket pickers. Nat. Struct. Mol. Biol. 2007, 14:1025-1040.
52. van Haaften G., Dalgliesh G.L., Davies H., Chen L., Bignell G., Greenman C., Edkins S., Hardy C., O'Meara S., Teague J., et al. Somatic mutations of the histone H3K27 demethylase gene UTX in human cancer. Nat. Genet. 2009, 41:521-523.
53. Yap K.L., Zhou M.M. Keeping it in the family: diverse histone recognition by conserved structural folds. Crit. Rev. Biochem. Mol. Biol. 2010, 45:488-505.
54. Yap D.B., Chu J., Berg T., Schapira M., Cheng S.W., Moradian A., Morin R.D., Mungall A.J., Meissner B., Boyle M., et al. Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethylation. Blood 2011, 117:2451-2459.
55. Ye T., Krebs A.R., Choukrallah M.A., Keime C., Plewniak F., Davidson I., Tora L. seqMINER: an integrated ChIP-seq data interpretation platform. Nucleic Acids Res. 2011, 39:e35.
56. Zhang Y., Liu T., Meyer C.A., Eeckhoute J., Johnson D.S., Bernstein B.E., Nusbaum C., Myers R.M., Brown M., Li W., Liu X.S. Model-based analysis of ChIP-Seq (MACS). Genome Biol. 2008, 9:R137.